SLC7A5 and glioma: A recent study reported that an increased oncometabolite 2-hydroxyglutarate in IDH mutated high-grade gliomas drives immunosuppression mechanisms by stimulating tryptophan metabolism with an increase of L-type amino acid transporter 1 (LAT1)45.